HEALWELL AI Provides Research Update on Peer-Reviewed MyHealthNB Study and Global Recognition of DARWEN(TM)

Peer-reviewed research in the Journal of Medical Internet Research reported statistically significant, self-reported improvements in patient empowerment and healthcare engagement associated with VeroSource's MyHealth app. HEALWELL's DARWEN™ AI abstract was selected among 10 additional submissions for the HealthAI Global Governance Forum 2026's “Beyond the Room” digital programme.

Analysis

The two signals should be underwritten separately: the VeroSource app study does not, on the evidence supplied, establish commercial impact for AIDX, while selection of a DARWEN abstract for a digital programme is visibility—not evidence of product adoption, clinical efficacy, or revenue. The study’s self-reported outcomes and association-based design may support a patient-engagement proposition, but do not establish causality or payer/provider return on investment. If independently replicated and tied to usage and retention data, such evidence could reduce procurement friction for digital health tools; it does not yet establish that outcome for AIDX.

Near term, this is a modest credibility signal with limited basis for revising earnings expectations. Over 1–3 months, the relevant catalysts are named customer deployments, renewal/usage metrics, and disclosure connecting evidence to paid contracts. Over 6–18 months, the opportunity depends on integration into clinical workflows and measurable outcomes; long procurement cycles, privacy requirements, and competing AI offerings can dilute value or delay conversion. Contrarian read: the market may overvalue conference visibility, while underweighting the potential value of credible evidence if it eventually translates into procurement. No trade is warranted on this item alone. Reassess if AIDX reports attributable commercial wins; thesis weakens if follow-up disclosures show no conversion or if independent evidence fails to replicate the engagement findings.

Key Decisions for Investors

• Do not treat this announcement as an earnings upgrade or conflate the VeroSource study with AIDX’s DARWEN programme; the supplied information does not establish a revenue link between them.
• Keep AIDX on a catalyst watchlist rather than initiating a position on this news. Verify whether the study was independently replicated and whether AIDX discloses paid deployments, renewals, or measurable usage tied to the relevant products.
• For any future long thesis, require evidence of customer conversion and repeat usage, not publication or forum selection alone. A lack of attributable commercial traction over the next 1–3 months would argue against paying a credibility premium.